Results 191 to 200 of about 143,679 (289)

PVN-LOT-602-D-004 [PDF]

, 2004
Collins, Lisa
core   +1 more source

Scalp‐negative medial temporal interictal epileptic discharges alter large‐scale brain networks: A simultaneous high‐density electroencephalographic and intracranial electroencephalographic study

Epilepsia, EarlyView.
Abstract Objective Interictal epileptiform discharges (IEDs) observed on scalp electroencephalography (EEG) serve as a diagnostic hallmark of epilepsy. However, only a small fraction of IEDs recorded by intracranial EEG (iEEG) are detectable on the scalp; the vast majority remain invisible on scalp recordings.
Nicolas Roehri, Pia De Stefano, Laurent Spinelli, Renaud Marquis, Stanislas Lagarde, Shahan Momjian, Margitta Seeck, Serge Vulliemoz   +7 more
wiley   +1 more source

The MadQCI Cloud Scenario: Quantum as a Service. [PDF]

Entropy (Basel)
Buruaga JS, Sebastián-Lombraña A, Méndez RB, Vicente RJ, Brito JP, Ortiz L, Martin V.   +6 more
europepmc   +1 more source

PSB-LOT-020-D-004 [PDF]

, 1985
Johnson, Timothy
core   +1 more source

Are single‐item global rating scales the same, better, or worse than multi‐item scales in epilepsy: A scoping review and meta‐analysis

Epilepsia, EarlyView.
Abstract Objective To examine the performance of single‐item global ratings (SIGRs) and multi‐item scales (MISs) in epilepsy research, and assess the influence of diverse constructs, study designs, and statistical methods. Methods Systematic scoping review following Preferred Reporting Items for Systematic reviews and Meta‐Analyses (PRISMA) and Joanna ...
Ann Subota, Mandavi Kashyap, Samuel Wiebe   +2 more
wiley   +1 more source

PSB-LOT-011-D-004 [PDF]

, 1985
unknown, un
core   +1 more source

L‐Relationship between uncertainty and average seizure frequency in clinical trials of antiseizure medications

Epilepsia, EarlyView.
Abstract Objective Antiseizure medications are approved based on clinical trials that demonstrate their efficacy as measured by reductions in seizure frequency (SF). When designing these trials, trialists must select inclusion criteria where SF can be reliably measured to maintain statistical power.
Wesley T. Kerr, Neo Kok, Katherine N. McFarlane, Advith S. Reddy, Lavanya Biju, Jacqueline A. French, Daniel M. Goldenholz   +6 more
wiley   +1 more source

Dynamic and concordance-assisted learning for risk stratification with application to Alzheimer's disease. [PDF]

Biostatistics
Li W, Li R, Feng Z, Ning J, Alzheimer’s Disease Neuroimaging Initiative.   +4 more
europepmc   +1 more source